Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002335 · ClinicalTrials.gov registry record · Phase 1
The Safety and Effectiveness of 524W91
A Phase 1 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00002335 is a Phase 1 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 18 participants.
The verdict
NCT00002335, a Phase 1 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.
Interventions
- DRUG Emtricitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002335
The ClinicalTrials.gov registry entry for NCT00002335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emtricitabine is the first listed.
NCT00002335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002335 about?
NCT00002335 is a clinical study titled "The Safety and Effectiveness of 524W91". To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in HIV-infected patients. To determine the effects of food on bioavailability of 524W91.
What is the current status of trial NCT00002335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants.
What interventions are being tested in trial NCT00002335?
The interventions under investigation include: Emtricitabine (DRUG).
Who is sponsoring clinical trial NCT00002335?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.